|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine显示文摘The non-classical HLA class I antigen HLA-G is an immune modulator which inhibits the functions of T cells, NK cells, and the Dendritic cells (DC). As a result, HLA-G expression in malignant cells may provide them with a mechanism to escape the immune surveillance. In melanoma, HLA-G antigen expression has been found in 30% of surgically removed lesions but in less than 1% of established cell lines. One possible mechanism underlying the differential HLA-G expression in vivo and in vitro is that the HLA-G gene is epigenetically repressed in melanoma cells in vitro. To test this hypothesis, we treated the HLA-G negative melanoma cell line OCM-1A with the DNA methyltransferase inhibitor 5-aza-2’-deoXycytidine (5-AC) and analyzed whether HLA-G expression can be restored. Our data strongly suggest that HLA-G is silenced as a result of CpG hypermethylation within a 5’ regulatory region encompassing 220 bp upstream of the start codon. After treatment, HLA-G mRNA expression was dramatically increased. Western blot and flow cytometry showed that HLA-G protein was induced. Interestingly, HLA-G cell surface expression on the 5-AC treated OCM-1 A cells is much less than that on the HLA-G positive JEG-3 cells while a similar amount of total HLA-G was observed. Possible mechanisms for the difference were analyzed in the study such as cell cold-treatment, peptide loading and antigen processing machinery components (APM) as well as β2 microglobulin (β2-m) expression. Data revealed that the APM component calreticulin might be involved in the lower HLA-G surface expression on OCM-1 A cells. Taken together, our results indicated that DNA methylation is an important epigenetic mechanism by which HLA-G antigen expression is modulated in melanoma cells in vitro. Furthermore, to the first time, we hypothesized that the deficiency of calreticulin might be involved in the low HLA-G surface expression on the 5-AC treated OCM-1 A cells. | Wei Hua YAN Ai Fen LIN Chien Chung CHANG Soldano FERRONE | 2005 | Cell Research2005，15，7： | 5 |
| 2 | Gallbladder tuberculosis: False-positive PET diagnosis of gallbladder cancer显示文摘Gallbladder tuberculosis (GT) is an extremely rare disease, and very few cases have been reported in the literature. The first case of GT was described in 1870 by Gaucher. A correct preoperative diagnosis of GT is unusual, and it is frequently confused with various gallbladder diseases. We present a new case of a patient who underwent surgery with the preoperative diagnosis of gallbladder cancer after a false positive positron emission tomography scan in the diagnostic work-up. | JM Ramia K Muffak A Fernández J Villar D Garrote JA Ferron | 2006 | World Journal of Gastroenterology2006，12，40： | 5 |
| 3 | Endocrine Regulation of Energy Metabolism by the Skeleton显示文摘 | Na Kyung Lee Hideaki Sowa Eiichi Hinoi Mathieu Ferron Jong Deok Ahn Cyrille Confavreux Romain Dacquin Patrick J. Mee Marc D. McKee Dae Young Jung Zhiyou Zhang Jason K. Kim Franck Mauvais-Jarvis Patricia Ducy Gerard Karsenty | 2007 | Cell2007，，3： | 5 |
| 4 | 851 resected cystic tumors of the pancreas: A 33-year experience at the Massachusetts General Hospital显示文摘 | Nakul P. Valsangkar Vicente Morales-Oyarvide Sarah P. Thayer Cristina R. Ferrone Jennifer A. Wargo Andrew L. Warshaw Carlos Fernández-del Castillo | 2012 | Surgery2012，，3： | 3 |
| 5 | Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors显示文摘Factors released by surrounding cells such as cancer-associated mesenchymal stromal cells(CA-MSCs)are involved in tumor progression and chemoresistance.In this study,we characterize the mechanisms by which naYve mesenchymal stromal cells(MSCs)can acquire a CA-MSCs phenotype.Ovarian tumor cells trigger the transformation of MSCs to CA-MSCs by expressing pro-tumoral genes implicated in the chemoresistance of cancer cells,resulting in the secretion of high levels of CXC chemokine receptors 1 and 2(CXCR1/2)ligands such as chemokine(C-X-C motif)ligand 1(CXCL1),CXCL2,and interleukin 8(IL-8).CXCR1/2 ligands can also inhibit the immune response against ovarian tumor cells.Indeed,through their released factors,CA-MSCs promote the differentiation of monocytes towards M2 macrophages,which favors tumor progression.When CXCR1/2 receptors are inhibited,these CA-MSC-activated macrophages lose their M2 properties and acquire an anti-tumoral phenotype.Both ex vivo and in vivo,we used a CXCR1/2 inhibitor to sensitize ovarian tumor cells to carboplatin and circumvent the pro-tumoral effects of CA-MSCs.Since high concentrations of CXCR1/2 ligands in patients*blood are associated with chemoresistance,CXCR1/2 inhibition could be a potential therapeutic strategy to revert carboplatin resistance. | Augustin Le Naour Melissa Prat Benolt Thibault Renaud Mével Léa Lemaitre Helene Leray Marie-Veronique Joubert Kimberley Coulson Muriel Golzio Lise Lefevre Eliane Mery Alejandra Martinez Gwénael Ferron Jean-Pierre Delord Agnès Coste Bettina Couderc | 2020 | Journal of Molecular Cell Biology2020，12，3： | 3 |
| 6 | Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection?显示文摘 | Ioannis T. Konstantinidis Andrew L. Warshaw Jill N. Allen Lawrence S. Blaszkowsky Carlos Fernandez-del Castillo Vikram Deshpande Theodore S. Hong Eunice L. Kwak Gregory Y. Lauwers David P. Ryan Jennifer A. Wargo Keith D. Lillemoe Cristina R. Ferrone | 2013 | Annals of Surgery2013，，4： | 3 |
| 7 | Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer显示文摘 | Jennifer Y. Wo Harvey J. Mamon Cristina R. Ferrone David P. Ryan Lawrence S. Blaszkowsky Eunice L. Kwak Yolanda D. Tseng Brian N. Napolitano Marek Ancukiewicz Richard S. Swanson Keith D. Lillemoe Carlos Fernandez-del Castillo Theodore S. Hong | 2013 | Radiotherapy and Oncology2013，，： | 2 |
| 8 | Lymphoepithelial cysts and cystic lymphangiomas: Underrecognized benign cystic lesions of the pancreas显示文摘AIM: To identify their diagnostic and prognostic clinical characteristics in a large series.METHODS: Retrospective review of clinicopathologic and imaging characteristics of patients diagnosed with lymphoepithelial cysts and cystic lymphangiomas of the pancreas at Massachusetts General Hospital.RESULTS: Twelve patients were identified between 1/1/1997 and 8/1/2007. Their median age was 55.5 years(range 19-78 years), and 6 were females. The le-sion was incidentally discovered in half of the patients.Contrast enhanced computed tomography demonstrat-ed that the cysts had thin walls, without calcifications, pancreatic duct dilation or pancreatic parenchyma inva-sion. Endoscopic ultrasound with fine needle aspiration(EUS/FNA) confirmed the diagnosis of a lymphoepithe-lial cyst in 3 patients, one of whom was spared an op-eration and continues to do well after 6 years. Eleven patients had a resection: 3 pancreaticoduodenecto-mies, 7 distal pancreatectomies, and 1 enucleation. The median size of the cysts was 3 cm(range 2-20 cm). At a median follow-up of 57 mo no recurrences or other pancreas-related conditions occurred.CONCLUSION: Lymphoepithelial cysts and cystic lymphangiomas of the pancreas can be diagnosed with a combination of contrast-enhanced computed tomog-raphy scans and EUS/FNA. If the lesion is asymptom-atic, an operation might be avoided. | Ioannis T Konstantinidis Avinash Kambadakone Onofrio A Catalano Dushyant V Sahani Vikram Deshpe David G Forcione Jennifer A Wargo Carlos Fernandez-del Castillo Keith D Lillemoe Andrew L Warshaw Cristina R Ferrone | 2014 | World Journal of Gastrointestinal Surgery2014，6，7： | 2 |
| 9 | Limitations of Ampullectomy in the Treatment of Nonfamilial Ampullary Neoplasms显示文摘 | Kevin K. Roggin MD Jen Jen J. Yeh MD Cristina R. Ferrone MD Elyn Riedel MS Hans Gerdes MD David S. Klimstra MD David P. Jaques MD Murray F. Brennan MD | 2005 | Annals of Surgical Oncology2005，，12： | 2 |
| 10 | Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure显示文摘 | Cristina R. Ferrone Rafael Pieretti-Vanmarcke Jordan P. Bloom Hui Zheng Jackye Szymonifka Jennifer A. Wargo Sarah P. Thayer Gregory Y. Lauwers Vikram Deshpande Mari Mino-Kenudson Carlos Fernández-del Castillo Keith D. Lillemoe Andrew L. Warshaw | 2012 | Surgery2012，，： | 2 |
| 11 | Seasonal study of dissolved CH4 , CO2 and N2O in a shallow tidal system of the bay of Cadiz (SW Spain) 显示文摘 | Ferron S Ortega T Gomez-Parra A | 2007 | Journal of Marine System2007，66，14： | 1 |
| 12 | The efficacy of silicone oil for complicated retinal detachment in the pediatric population 显示文摘 | Ferrone PJ Machemer R Juan F | 1996 | Eur J Ophthalmol1996，6，4： | 1 |
| 13 | Insulin signaling in os-teoblasts integrates bone remodeling and energy metabolism显示文摘 | FERRON M WEI J YOSHIZAWA T | | 0，，02： | 1 |
| 14 | 查看详情显示文摘 | Gohil P Evans T E Ferron J R Moyer R A Petty C C Burrell K H Casper T A Garofalo A M Hyatt A W Jayakumar R J Kessel C Kim J Y La Haye R J Lohr J Luce T C Makowski M A Mazon D Menard J Murakami M Politzer P A Prater R Wade M R | | 0，，： | 1 |
| 15 | Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation显示文摘 | Seliger B Ritz U Ferrone S | 2006 | Int J Cancer2006，118，1： | 1 |
| 16 | A Non-ATP-competitive Inhibitor of BCR-ABL Overrides Resistance显示文摘 | Foy E Ferron JC | 2005 | Proc Natl Acad Scid USA2005，102，8： | 1 |
| 17 | Perioperative C19 -9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma 显示文摘 | Ferrone C R Finkelstein D M Thayer S P | 2006 | J Clin Oncol2006，24，18： | 1 |
| 18 | Periope- rative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma显示文摘 | Ferrone CR Finkelstein DM Thayer SP | 2006 | JClin 0ncol2006，24，18： | 1 |
| 19 | Biological control of insect pests by entomogenous fungi显示文摘 | Ferron P | 1978 | Annul Rev Entomol1978，23，： | 1 |
| 20 | Population pharmacokinetics of sirolimus in kidney transplant patients 显示文摘 | Ferron GM Mishina EV Zimmerman JJ | 1997 | Clin Pharmacol Ther1997，61，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员